MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ
3.900
0.000
0.00%
After Hours: 3.900 0 0.00% 16:10 06/05 EDT
OPEN
3.950
PREV CLOSE
3.900
HIGH
4.070
LOW
3.890
VOLUME
11.54K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
2.660
MARKET CAP
70.69M
P/E (TTM)
-6.2883
1D
5D
1M
3M
1Y
5Y
1D
Alterity Therapeutics management to meet with BTIG
TipRanks · 2d ago
Weekly Report: what happened at ATHE last week (0525-0529)?
Weekly Report · 4d ago
Weekly Report: what happened at ATHE last week (0518-0522)?
Weekly Report · 05/25 09:05
Alterity Therapeutics Presents On Multiple System Atrophy Program Including Its Novel Imaging And Biomarker Approach, Phase 2 Data, And Current Plans To Advance ATH434 Into Phase 3 Clinical Development.
Benzinga · 05/19 11:31
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
TipRanks · 05/19 10:30
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Barchart · 05/19 06:25
Alterity data support advancing ATH434 into Phase 3 MSA trial
PUBT · 05/19 00:59
Weekly Report: what happened at ATHE last week (0511-0515)?
Weekly Report · 05/18 09:05
More
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ: ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.